NCT04443751View on ClinicalTrials.gov

A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

September 10, 2020

Primary Completion Date

February 28, 2023

Study Completion Date

February 28, 2023

Conditions
AMLMDS
Interventions
DRUG

SHR-1702

SHR-1702 monotherapy, administered IV

Trial Locations (1)

300041

Blood disease hospital of Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04443751 - A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Biotech Hunter | Biotech Hunter